ZN 043
Alternative Names: ZN-043Latest Information Update: 05 Oct 2023
At a glance
- Originator Zerion Pharma
- Class Antithrombotics; Cardiovascular therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cardiovascular disorders; Deep vein thrombosis
Most Recent Events
- 04 Oct 2023 ZN 043 is available for licensing as of 04 Oct 2023. https://www.zerion.eu/partnering (Zerion Pharma website, October 2023)
- 04 Oct 2023 Preclinical trials in Cardiovascular disorders in Denmark (PO) (Zerion Pharma pipeline, October 2023)
- 04 Oct 2023 Preclinical trials in Deep vein thrombosis in Denmark (PO) (Zerion Pharma pipeline, October 2023)